Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on January 23, 2024. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers. The report clarifies that the Board of Directors determined no bonuses would be granted for the fiscal years ended December 31, 2022, or 2023, and no bonuses would be accrued for 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Named Executive Officer | Position | 2022 Total Compensation | 2022 Bonus |
|---|---|---|---|
| James N. Woody | CEO and Director | $463,500 | $0 |
| Ozan Pamir | CFO | $309,000 | $0 |
| Quan Anh Vu | Former COO/CBO | $735,190 | $0 |
| Jonathan Rothbard | Chief Scientific Officer | $268,906 | $0 |
Note: Quan Anh Vu's 2022 total compensation includes $333,490 in termination payments. No executive received stock or option awards in 2022.
Material Changes Versus Prior Period
- Bonus Determination: The filing revises the Summary Executive Compensation Table for the fiscal year ended December 31, 2022, to reflect that the "2022 Bonuses" were determined to be $0. Previously, these amounts were omitted from the Annual Report on Form 10-K because they were undetermined at the time of filing.
- Compensation Structure: Unlike 2021, where executives received significant option awards and bonuses (e.g., CEO received $50,000 bonus and $4.26M in options), 2022 compensation consisted solely of salary and, in one case, termination payments.
- Executive Departure: Quan Anh Vu's employment agreement was terminated effective January 15, 2023, resulting in significant "All Other Compensation" in 2022.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business operations. The primary disclosure is the formal determination that no bonuses will be accrued for 2024. The filing notes that the company previously filed Amendment No. 1 to its 2022 Annual Report to address the omission of final bonus amounts.
Important Facts for Investor Verification
- Company Identity: Verify that the filing pertains to 180 Life Sciences Corp. (Ticker: ATNF), not Forum Markets Inc.
- Compensation Policy: Confirm the Board's decision to eliminate bonuses for 2022, 2023, and 2024, indicating a shift in cash conservation or performance criteria.
- Termination Costs: Review the $333,490 paid to former COO Quan Anh Vu as part of his 2022 compensation package.
- Equity Dilution: Note the absence of new stock or option awards in 2022 compared to the significant grants made in 2021.